INDIGO Home University of Illinois at Urbana-Champaign logo uic building uic pavilion uic student center

Co-morbid Disruptive Behavior Disorder and Aggression Predict Functional Outcomes and Differential Response to Risperidone Versus Divalproex in Pharmacotherapy for Pediatric Bipolar Disorder

Show simple item record

Bookmark or cite this item: http://hdl.handle.net/10027/8418

Files in this item

File Description Format
PDF nps4BDA.pdf (122KB) (no description provided) PDF
Title: Co-morbid Disruptive Behavior Disorder and Aggression Predict Functional Outcomes and Differential Response to Risperidone Versus Divalproex in Pharmacotherapy for Pediatric Bipolar Disorder
Author(s): West, Amy E.; Weinstein, Sally M.; Celio, Christine I.; Henry, David; Pavuluri, Mani N.
Abstract: Objective: Co-morbid diagnoses, such as disruptive behavior disorders (DBDs) and high levels of aggression, are extremely common among youth with pediatric bipolar disorder (PBD) and may interfere with treatment response; however, they have rarely been examined as predictors of response to pharmacotherapy. The current study examines co-morbid DBD and aggression prospectively as predictors of pharmacotherapy outcome, as well as potential moderators of response to a specific medication (risperidone vs. divalproex), among children with PBD. Methods: Data are from a prospective 6-week double-blind, placebo-controlled, randomized outpatient medication treatment trial of risperidone versus divalproex for manic episodes in 65 children 8–18 with PBD. Outcome measures were administered at pretest, post-test, and weekly during the 6 weeks of treatment. Mixed-effects regression models were used to examine pharmacotherapy response. Results: Results indicated that youthwith co-morbidDBDexperienced greater improvement in manic symptoms in response to risperidone versus divalproex, whereas youth with non-co-morbid DBD experienced similar trajectories of symptom improvement in bothmedication groups. In addition, the non-DBD group experienced greater improvement in global functioning over time as compared with youth with co-morbid-DBD, and this gap increased over the course of treatment. Results also indicated that high-aggression youth experienced worse global functioning by end treatment versus low-aggression youth. Conclusions: In conclusion, a co-morbid diagnosis of DBD and/or high levels of aggressive symptoms in youth with PBD may be important clinical predictors of variation in treatment response to pharmacotherapy. These findings may help researchers and clinicians develop tailored treatment approaches that optimize symptom and functional outcomes.
Issue Date: 2011-12
Publisher: Mary Ann Liebert
Citation Info: West, A. E., Weinstein, S. M., Celio, C. I., Henry, D., & Pavuluri, M. N. 2011. Co-morbid Disruptive Behavior Disorder and Aggression Predict Functional Outcomes and Differential Response to Risperidone Versus Divalproex in Pharmacotherapy for Pediatric Bipolar Disorder. Journal of Child and Adolescent Psychopharmacology, 21(6): 545-553. DOI: 10.1089/cap.2010.0140
Type: Article
Description: This is a copy of an article published in the Journal of Child and Adolescent Psychopharmacology © 2011 Copyright Mary Ann Liebert, Inc.; Journal of Child and Adolescent Psychopharmacology is available online at: http://www.liebertonline.com. DOI: 10.1089/cap.2010.0140
URI: http://hdl.handle.net/10027/8418
ISSN: 1044-5463
Sponsor: This research was funded by NIH 1 K23 RR018638-01 and NIHMO1- RR-13987. Study drugs and matching placebo were provided by Johnson and Johnson and Abbott Pharmaceuticals.
Date Available in INDIGO: 2012-07-25
 

This item appears in the following Collection(s)

Show simple item record

Statistics

Country Code Views
United States of America 56
China 14
United Kingdom 11
Serbia 2
Germany 1

Browse

My Account

Information

Access Key